{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:31:30Z","timestamp":1790127090379,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic retinopathy (DR) is the leading cause of irreversible blindness in adults, with inflammation playing a critical role in its pathogenesis, particularly involving the complement system (CS). Components of the complement cascade, such as C3a and C5a, have been identified in both vitreous and plasma samples from individuals with DR. This study aimed to evaluate plasma concentrations of C3a and C5a in relation to DR onset and severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 150 patients with diabetes mellitus (DM) underwent ophthalmic examination and were categorized into groups: without DR (control group), mild\/moderate\/severe non-proliferative DR (NPDR) and proliferative DR (PDR). Plasma C3a and C5a levels were measured using sandwich enzyme-linked immunosorbent assays (ELISA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Significant elevations in C3a levels were found in severe NPDR (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02) and PDR (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) groups compared to controls. Furthermore, severe\/proliferative DR exhibited higher C3a levels than mild\/moderate NPDR (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.015). No significant differences in C5a concentrations were observed among the groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest the involvement of complement in the pathogenesis of DR, and the association of C3a with DR severity highlights its potential as a prognostic biomarker and therapeutic target.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00821-6","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:55:15Z","timestamp":1773366915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["C3a and C5a plasma concentrations in patients with diabetic retinopathy: a cross-sectional study"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3163-8854","authenticated-orcid":false,"given":"Paula Basso","family":"Dias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5573-260X","authenticated-orcid":false,"given":"Iara","family":"Messias-Reason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2897-6833","authenticated-orcid":false,"given":"Germano Ramos","family":"Boff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1234-8093","authenticated-orcid":false,"given":"Kenzo","family":"Hokazono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Nisihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"821_CR1","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.ophtha.2006.10.023","volume":"114","author":"R Varma","year":"2007","unstructured":"Varma R, Macias GL, Torres M, Klein R, Pe\u00f1a FY, Azen SP. Biologic risk factors associated with diabetic retinopathy. Ophthalmology. 2007;114:1332\u201340.","journal-title":"Ophthalmology"},{"issue":"5 Suppl","key":"821_CR2","first-page":"786","volume":"98","author":"Grading diabetic retinopathy","year":"1991","unstructured":"Grading diabetic retinopathy. from stereoscopic color fundus photographs\u2013an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98(5 Suppl):786\u2013806.","journal-title":"Ophthalmology"},{"key":"821_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/978-1-4614-5441-0_10","volume":"771","author":"JM Tarr","year":"2012","unstructured":"Tarr JM, Kaul K, Wolanska K, Kohner EM, Chibber R. Retinopathy in diabetes. Adv Exp Med Biol. 2012;771:88\u2013106.","journal-title":"Adv Exp Med Biol"},{"key":"821_CR4","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/j.1464-5491.2007.02217.x","volume":"24","author":"AM Spijkerman","year":"2007","unstructured":"Spijkerman AM, Gall MA, Tarnow L, et al. Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in Type 2 diabetes. Diabet Med. 2007;24:969\u201376.","journal-title":"Diabet Med"},{"issue":"4","key":"821_CR5","first-page":"575","volume":"69","author":"F Jiang","year":"2024","unstructured":"Jiang F, Lei C, Chen Y, Zhou N, Zhang M. The complement system and diabetic retinopathy. Surv Ophthalmol. 2024;69(4):575\u201384.","journal-title":"Surv Ophthalmol"},{"key":"821_CR6","doi-asserted-by":"publisher","first-page":"106863","DOI":"10.1016\/j.imlet.2024.106863","volume":"267","author":"PB Dias","year":"2024","unstructured":"Dias PB, Messias-Reason I, Hokazono K, Nisihara R. The role of mannose-binding lectin (MBL) in diabetic retinopathy: A scoping review. Immunol Lett. 2024;267:106863. https:\/\/doi.org\/10.1016\/j.imlet.2024.106863.","journal-title":"Immunol Lett"},{"key":"821_CR7","first-page":"1","volume":"9","author":"A Sheemar","year":"2023","unstructured":"Sheemar A, Goel P, Thakur PS, Takkar B, Kaur I, Rani PK, Tyagi M, Basu S, Venkatesh P. Diabetes, Diabetic Retinopathy, and Inflammatory Disorders. Ocul Immunol Inflamm. 2023;9:1\u201314.","journal-title":"Ocul Immunol Inflamm"},{"key":"821_CR8","first-page":"1588","volume":"17","author":"C Luo","year":"2011","unstructured":"Luo C, Chen M, Xu H. Complement gene expression and regulation in mouse retina and retinal pigment epithelium\/choroid. Mol Vis. 2011;17:1588\u201397.","journal-title":"Mol Vis"},{"key":"821_CR9","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1016\/j.molimm.2007.06.145","volume":"44","author":"P Jha","year":"2007","unstructured":"Jha P, Bora PS, Bora NS. The role of complement system in ocular diseases including uveitis and macular degeneration. Mol Immunol. 2007;44:3901\u20138.","journal-title":"Mol Immunol"},{"key":"821_CR10","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1016\/j.ajpath.2018.06.018","volume":"188","author":"M Sircar","year":"2018","unstructured":"Sircar M, Rosales IA, Selig MK, et al. Complement 7 is up-regulated in human early diabetic kidney disease. Am J Pathol. 2018;188:2147\u201354.","journal-title":"Am J Pathol"},{"issue":"4","key":"821_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00125-021-05380-z","volume":"64","author":"SB Catrina","year":"2021","unstructured":"Catrina SB, Zheng X. Hypoxia and hypoxia-inducible factors in diabetes and its complications. Diabetologia. 2021;64(4):709\u201316. https:\/\/doi.org\/10.1007\/s00125-021-05380-z.","journal-title":"Diabetologia"},{"key":"821_CR12","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1124\/pr.111.005223","volume":"65","author":"A Klos","year":"2013","unstructured":"Klos A, Wende E, Wareham KJ, Monk PN. International union of basic and clinical pharmacology. (corrected). LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol Rev. 2013;65:500\u201343. https:\/\/doi.org\/10.1124\/pr.111.005223.","journal-title":"Pharmacol Rev"},{"key":"821_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4049\/jimmunol.1100491","volume":"187","author":"M Morigi","year":"2011","unstructured":"Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, et al. Alternative pathway activation of complement by shiga toxin promotes exu- berant C3a formation that triggers microvascular thrombosis. J Immunol. 2011;187:172\u201380. https:\/\/doi.org\/10.4049\/jimmunol.1100491.","journal-title":"J Immunol"},{"key":"821_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/02713680802546658","volume":"34","author":"DN Cortright","year":"2009","unstructured":"Cortright DN, Meade R, Waters SM, Chenard BL, Krause JE. C5a, but not C3a, increases VEGF secretion in ARPE-19 human retinal pigment epithelial cells. Curr Eye Res. 2009;34:57\u201361. https:\/\/doi.org\/10.1080\/02713680802546658.","journal-title":"Curr Eye Res"},{"issue":"11","key":"821_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1167\/iovs.61.11.39","volume":"61","author":"N Mandava","year":"2020","unstructured":"Mandava N, Tirado-Gonzalez V, Geiger MD, Patnaik JL, Frazer-Abel A, Lynch AM, et al. Complement Activation in the Vitreous of Patients With Proliferative Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2020;61(11):39. https:\/\/doi.org\/10.1167\/iovs.61.11.39.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"821_CR16","first-page":"1104","volume":"43","author":"VB Gerl","year":"2002","unstructured":"Gerl VB, Bohl J, Pitz S, Stoffelns B, Pfeiffer N, Bhakdi S. Extensive deposits of complement C3d and C5b-9 in the choriocapillaris of eyes of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci. 2002;43(4):1104\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"821_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00417-012-2024-6","volume":"251","author":"D Muramatsu","year":"2013","unstructured":"Muramatsu D, Wakabayashi Y, Usui Y, Okunuki Y, Kezuka T, Goto H. Correlation of complement fragment C5a with inflammatory cytokines in the vitreous of patients with proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2013;251:15\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"821_CR18","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1097\/IAE.0000000000002288","volume":"39","author":"N Manoharan","year":"2018","unstructured":"Manoharan N, Patnaik JL, Olson JL. Increased complement levels in human vitreous aspirates of proliferative diabetic retinopathy and retinal detachment eyes. Retina. 2018;39:2212\u20138.","journal-title":"Retina"},{"key":"821_CR19","doi-asserted-by":"publisher","first-page":"20341","DOI":"10.1038\/srep20341","volume":"6","author":"L Zhang","year":"2016","unstructured":"Zhang L, Li Y, Payne J, Srivastava S, Fan X, Fung J, Li X, Kern TS, Lin F. Presence of retinal pericyte-reactive autoantibodies in diabetic retinopathy patients. Sci Rep. 2016;6:20341. https:\/\/doi.org\/10.1038\/srep20341.","journal-title":"Sci Rep"},{"issue":"4","key":"821_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1167\/tvst.11.4.13","volume":"11","author":"JM Smith","year":"2022","unstructured":"Smith JM, Mandava N, Tirado-Gonzalez V, et al. Correlation of Complement Activation in Aqueous and Vitreous in Patients With Proliferative Diabetic Retinopathy. Transl Vis Sci Technol. 2022;11(4):13. https:\/\/doi.org\/10.1167\/tvst.11.4.13.","journal-title":"Transl Vis Sci Technol"},{"issue":"2","key":"821_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.arcmed.2018.06.003","volume":"49","author":"K Hokazono","year":"2018","unstructured":"Hokazono K, Beliz\u00e1rio FS, Portugal V, Messias-Reason I, Nisihara R. Mannose Binding Lectin and Pentraxin 3 in Patients with Diabetic Retinopathy. Arch Med Res. 2018;49(2):123\u20139. https:\/\/doi.org\/10.1016\/j.arcmed.2018.06.003.","journal-title":"Arch Med Res"},{"issue":"3","key":"821_CR22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1210\/er.2014-1099","volume":"36","author":"P Ghosh","year":"2015","unstructured":"Ghosh P, Sahoo R, Vaidya A, Chorev M, Halperin JA. Role of complement and complement regulatory proteins in the complications of diabetes. Endocr Rev. 2015;36(3):272\u201388. https:\/\/doi.org\/10.1210\/er.2014-1099.","journal-title":"Endocr Rev"},{"issue":"11","key":"821_CR23","doi-asserted-by":"publisher","first-page":"103757","DOI":"10.1016\/j.drudis.2023.103757","volume":"28","author":"S Rathi","year":"2023","unstructured":"Rathi S, Hasan R, Ueffing M, Clark SJ. Therapeutic targeting of the complement system in ocular disease. Drug Discov Today. 2023;28(11):103757. https:\/\/doi.org\/10.1016\/j.drudis.2023.103757.","journal-title":"Drug Discov Today"},{"issue":"1","key":"821_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00281-017-0649-6","volume":"40","author":"SJ Clark","year":"2018","unstructured":"Clark SJ, Bishop PN. The eye as a complement dysregulation hotspot. Semin Immunopathol. 2018;40(1):65\u201374. https:\/\/doi.org\/10.1007\/s00281-017-0649-6.","journal-title":"Semin Immunopathol"},{"key":"821_CR25","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2337\/dc16-2641","volume":"40","author":"SD Solomon","year":"2017","unstructured":"Solomon SD, Chew E, Duh EJ, et al. Diabetic retinopathy: a position statement by the American Diabetes Association (published correction appears in Diabetes Care. Diabetes Care. 2017;40:412\u20138.","journal-title":"Diabetes Care"},{"issue":"13","key":"821_CR26","doi-asserted-by":"publisher","first-page":"8191","DOI":"10.1167\/iovs.13-12428","volume":"54","author":"L Cheng","year":"2013","unstructured":"Cheng L, Bu H, Portillo JA, Li Y, Subauste CS, Huang SS, Kern TS, Lin F. Modulation of retinal M\u00fcller cells by complement receptor C5aR. Invest Ophthalmol Vis Sci. 2013;54(13):8191\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"821_CR27","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3389\/fimmu.2019.01007","volume":"10","author":"DH Park","year":"2019","unstructured":"Park DH, Connor KM, Lambris JD. The challenges and promise of complement therapeutics for ocular diseases. Front Immunol. 2019;10:1007.","journal-title":"Front Immunol"},{"key":"821_CR28","unstructured":"Apellis Pharmaceuticals, Inc. Apellis presents Phase 3 functional analyses of SYFOVRETM (pegcetacoplan injection) for geographic atrophy - apellis Pharmaceuticals, Inc (Internet) Apellis Pharm. 2023 Available from: https:\/\/investors.apellis.com\/news-releases\/news-release-details\/apellis-presents-phase-3-functional-analyses-syfovretm"},{"key":"821_CR29","unstructured":"Astellas Pharma. Iveric Bio Receives U.S. FDA approval for IZERVAYTM (avacincaptad pegol intravitreal solution), a New treatment for geographic atrophy (Internet). Astellas. 2023. Available from: https:\/\/www.astellas.com\/en\/news\/28281"},{"key":"821_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nrneph.2017.31","volume":"13","author":"A Flyvbjerg","year":"2017","unstructured":"Flyvbjerg A. The role of the complement system in diabetic nephropathy. Nat Rev Nephrol. 2017;13:311\u20138.","journal-title":"Nat Rev Nephrol"},{"key":"821_CR31","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.2337\/diabetes.53.10.2653","volume":"53","author":"X Qin","year":"2004","unstructured":"Qin X, Goldfine A, Krumrei N, et al. Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes. 2004;53:2653\u201361.","journal-title":"Diabetes"},{"issue":"1","key":"821_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.atherosclerosis.2006.06.013","volume":"192","author":"R Oksjoki","year":"2007","unstructured":"Oksjoki R, Kovanen PT, Mayranpaa MI, Laine P, Blom AM, Meri S, et al. Comple- ment regulation in human atherosclerotic coronary lesions. Immunohistochemical evidence that C4b-binding protein nega- tively regulates the classical complement pathway, and that C5b-9 is formed via the alternative complement pathway. Atherosclerosis. 2007;192(1):40\u20138.","journal-title":"Atherosclerosis"},{"issue":"10","key":"821_CR33","doi-asserted-by":"publisher","first-page":"e79661","DOI":"10.1371\/journal.pone.0079661","volume":"8","author":"M Adhi","year":"2013","unstructured":"Adhi M, Cashman SM, Kumar-Singh R. Adeno-associated virus mediated delivery of a non-membrane targeted human soluble CD59 attenuates some aspects of diabetic retinopathy in mice. PLoS ONE. 2013;8(10):e79661. https:\/\/doi.org\/10.1371\/journal.pone.0079661.","journal-title":"PLoS ONE"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00821-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00821-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00821-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:49:10Z","timestamp":1781639350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00821-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["821"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00821-6","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a cross-sectional study, approved by the Institutional Research Ethics Committee of Federal University of Paran\u00e1, under protocol n\n                      o\n                      329.141. All participants signed an informed consent. The study was conducted according to the Good Clinical Practice guidelines and the Declaration of Helsinki","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}